Investigational drug · Phase 2
VX-670
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Myotonic Dystrophy Type 1 (DM1).
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "VX-670"
First trial start
2024
Feb 20, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VX-670", any sponsor or status.
Conditions studied
As listed on its trial records.
- Myotonic Dystrophy Type 1 (DM1)
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "VX-670" as an intervention, largest first.
- A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)Active, not recruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT06185764 · 47 participants · Start Feb 20, 2024 · Primary completion Feb 2, 2027
Drug: VX-670; Placebo · For: Myotonic Dystrophy Type 1 (DM1)
Sites: San Carlos, California; Gainesville, Florida; Fairway, Kansas · 26 sites in all
- A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type IEnrolling by invitation
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT06926621 · 44 participants (planned) · Start Apr 28, 2025 · Primary completion Jan 30, 2029
Drug: VX-670 · For: Myotonic Dystrophy Type 1 (DM1)
Sites: St Louis, Missouri; Winston-Salem, North Carolina; Richmond, Virginia · 16 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Myotonic Dystrophy Type 1 (DM1)
- Del-desiranAOC 1001Phase 33 trials
Avidity Biosciences, Inc. · DM1, Myotonic Dystrophy, Myotonic Dystrophy 1
- zeleciment basivarsenDYNE-101Phase 32 trials
Dyne Therapeutics · Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Vertex Pharmaceuticals.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.